Severe acute renal failure in an HIV-infected patient after only 2 weeks of tenofovir-based antiretroviral therapy

AIDS Patient Care and STDs

Volumn 25, Issue 8, 2011, Pages 457-460

  Pavie, Juliette ^a   Scemla, Anne ^a   Bouldouyre, Marie Anne ^a   Pillebout, Evangéline ^b   Verine, Jérome ^a   Molina, Jean Michel ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; TENOFOVIR;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ADULT; ALCOHOLISM; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CREATININE BLOOD LEVEL; HEMODIALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY BIOPSY; LUNG TUBERCULOSIS; MALE; MALE HOMOSEXUAL; NEPHRECTOMY; UROGENITAL TRACT TUMOR; UROGENITAL TUBERCULOSIS;

ACUTE KIDNEY INJURY; ADENINE; ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; TREATMENT OUTCOME;

EID: 80052790456     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2011.0056     Document Type: Article

References (25)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. US Department of Health and Human Services, Rockville, Maryland. January 1, 2011. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL .pdf (Last accessed June 16, 2011).
2. Tanji N, Tanji K, Kambham N et al. Adefovir nephrotoxicity: Possible role of mitochondrial DNA depletion. Hum Pathol 2001;32:734-740. (Pubitemid 32726898)
3. Meier P, Dautheville-Guibal S, Ronco P et al. Cidofovirinduced end-stage renal failure. Nephrol Dial Transplant 2002;17:148-149.
4. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004;292:191-201. (Pubitemid 38917996)
5. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Oncedaily atazanavir/ritonavir versus twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1- infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-655.
6. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: Renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51:496-505.
7. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36: 1070-1073. (Pubitemid 36513295)
8. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: Report of 7 cases. J Acquir Immune Defic Syndr 2004, 35: 269-273. (Pubitemid 38280652)
9. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatmen, compared with nucleoside reverse transcriptase inhibitor treatment. Clin Infect Dis 2005;40: 1194-1198. (Pubitemid 40490248)
10. Rifkin BS, Perazella MA. Tenofovir associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 2004; 117:282-284. (Pubitemid 39092726)
11. Zimmermann AE, Pizzoferrato T, Bedford J, Morris, A, Hoffman R, Braden G. Tenofovir associated acute and chronic kidney disease: A case of multiple drug interactions. Clin Infect Dis 2006;42:283-290. (Pubitemid 43054205)
12. Gupta SK. Tenofovir-associated Fanconi syndrome: Review of the FDA adverse event reporting system.AIDS Patient Care STDs 2008;22:99-103. (Pubitemid 351252586)
13. Crane HM, Kestenbaum B, Harrington RD, Kitahata MM. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS 2007;21:1431-1439. (Pubitemid 46988003)
14. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, DAgati VD, Markowitz GS. Tenofovir nephrotoxicity: Acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010;78:1171-1177.
15. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009; 23:689-696.
16. Rodríguez-Nóvoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tehofovir: A pharmacogenetic study. Clin Infect Dis 2009,48:e108-116.
17. Goicoechea M, Liu S, Best B, et al. Greater tenofovirassociated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008;197:102-108. (Pubitemid 351263473)
18. Kiser JJ, Carten CL, Aquilante PL, et al. The effect of Lopinavir/ritonavir on the renal clearance of tenofovir in HIV infected patients. Clin Pharmacol Ther 2008;83: 265-272.
19. Young B, Buchacz K, Moorman A, Wood KC, Brooks JT; HIV Outpatient Study (HOPS) Investigators. Renal function in patients with preexisting renal disease receiving tenofovir- containing highly active antiretroviral therapy in the HIV outpatient study. AIDS Patient Care STDs 2009;23: 589-592.
20. Daar E, Tierney C, Fischl M, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: A randomized rrial. Ann Intern Med 2011;154: 445-456.
21. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010;24:1667-1658.
22. Buchacz K, Young B, Baker RK, et al. Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/ atazanavir in the HIV Outpatient Study (HOPS) cohort. J Acquir Immune Defic Syndr 2006;43:626-628. (Pubitemid 44885634)
23. Agarwala E, Daar, C Tierney, et al. ACTG 5202: Final Results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatment-naive HIV-infected patients [Abstract 59LB]. 17th Conference on Retroviruses & Opportunistic Infections (CROI 2010). San Francisco. February 16-19, 2010.
24. Ray AS, Vela KL, Robinson KL, Kearney BP, Rhodes GR. Role of intestinal absorption in increased tenofovir disoproxil fumarate is co-administred with atazanavir or lopinavir /ritonavir. In: Program and Abstracts of the 7th International Workshop on clinical Pharmacology of HIV Therapy. Lisbon: 2006.
25. Izzedine H, Hulot JS, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006;194:1481-1491. (Pubitemid 44851889)